Skip to content

Homeopathic Treatment for Allergic Rhinitis: Comparing Arundo Mauritanica with Individualized Medicines

A Randomized Comparative Study to Evaluate Effectiveness of Arundo Mauritanica versus Individualized Homoeopathic Medicine for Allergic Rhinitis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094888
Enrollment
60
Registered
2025-09-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: Homeopathic Medicines Pill form of administration: Oral route of administration 30 pill size Centisimal scale First dose after case taking Repetition of doses according to follow up

Sponsors

Bakson Homeoepathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed cases of allergic rhinitis according to ARIA guidelines Participants with mild to moderate symptoms of allergic rhinitis. Willing to provide written informed consent. Participants who have not taken anti-allergic medications for at least 2 weeks prior to enrollment.

Exclusion criteria

Exclusion criteria: Participants with nasal polyps, deviated nasal septum, chronic sinusitis, asthma, or other systemic illnesses. Participants already under long-term antihistamines, corticosteroids, or immunotherapy. Pregnant or lactating women. Participants with any life-threatening illnesses (e.g., malignancies, uncontrolled systemic diseases) or classified as part of a vulnerable population. Participants with psychiatric disorders or cognitive impairment affecting their ability to give consent or adhere to protocol. Participants already participating in another clinical trials.

Design outcomes

Primary

MeasureTime frame
To evaluate the change in allergic rhinitis symptoms using the Total Nasal Symptom Score (TNSS) in both groups.Timepoint: 6 months for patient recruitment and intervention 6 months for follow ups 2 months for data analysis and interpretation 2 months of report writing.

Secondary

MeasureTime frame
To assess the improvement in quality of life using the Mini Rhinoconjunctivitis Quality of Life Questionnaire. Evaluate changes in serum IgE levels pre- and post treatment. Timepoint: 6 months for patient recruitment and intervention 6 months for follow ups 2 months for data analysis and interpretation 2 months of report writing.

Countries

India

Contacts

Public ContactDr Rashid Akhtar

Bakson Homoeopathic Medical College and Hospital

doc.priyamalik@gmail.com8802756050

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026